Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

BUILD-1: A Randomized Placebo-controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis

King, Talmadge E., Behr, Jürgen, Brown, Kevin K., du Bois, Roland M., Lancaster, Lisa, de Andrade, Joao A., Stähler, Gerd, Leconte, Isabelle, Roux, Sébastien, Raghu, Ganesh · 2008 · American Journal of Respiratory and Critical Care Medicine

Abstract

Rationale: Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal lung disease lacking effective treatment. Objectives: To determine the effects of bosentan on exercise capacity and time to disease progression in patients with IPF. Methods: In a double-blind, multicenter trial, patients with IPF were randomized to receive oral bosentan 62.5 mg twice daily for 4 weeks, increased to 125 mg twice daily thereafter, or placebo, for 12 months or longer. The primary efficacy endpoint was change from baseline up to Month 12 in exercise capacity, as measured by a modified six-minute-walk test. Secondary endpoints were time to death or disease progression (worsening pulmonary function tests [PFTs] or acute decompensation), change in PFT scores, and quality of life (QOL) assessed using Short-Form 36 and St. George's Respiratory Questionnaire. Measurements and Main Results: A total of 158 patients randomly received bosentan (n = 74) or placebo (n = 84). Bosentan showed no superiority over placebo in six-minute-walk distance (6MWD) up to Month 12, the primary efficacy endpoint. A trend in favor of bosentan was observed in the secondary endpoint of time to death or disease progression (hazard ratio [HR], 0.613; 95% confidence interval [CI], 0.328−1.144; P = 0.119), which was more pronounced in a patient subgroup diagnosed using surgical lung biopsy (post hoc analysis; HR, 0.315; 95% CI, 0.126−0.789; P = 0.009). Changes from baseline up to Month 12 in assessments of dyspnea and QOL favored treatment with bosentan. No unexpected adverse events were reported. Conclusions: Bosentan treatment in patients with IPF did not show superiority over placebo on 6MWD. A trend in delayed time to death or disease progression, and improvement in QOL, was observed with bosentan. The more pronounced treatment effect in patients with biopsy-proven IPF warrants further investigation. Clinical trial registered with www.clinicaltrials.gov (NCT00071461).

Overview

Integrity signals

Registry

Crossref · 10.1164/rccm.200705-732oc

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 30 references

Research works printed but not linked: 10

  1. 1996, Am J Physiol, 271, L538
  2. 2003, Proc Am Thorac Soc, 3, A524
  3. 2006, Annual Congress of the European Respiratory Society, 28, 571s
  4. 2006, Chest, 130, 282S
  5. 2006, Chest, 130, 151S
  6. 2007, Am J Respir Crit Care Med, 175, A567
  7. 2006, Annual Congress of the European Respiratory Society, 28, 383s
  8. 1971, Am Rev Respir Dis, 103, 57
  9. 1981, Am Rev Respir Dis, 123, 185
  10. 1982, Bull Eur Physiopathol Respir, 18, 419

Cited by

See all 506

Metadata

Authors
King, T. E., Behr, J., Brown, K. K., du Bois, R. M., Lancaster, L., de Andrade, J. A., Stähler, G., Leconte, I., Roux, S., & Raghu, G.
Affiliations
  • University of California, San Francisco (US)
  • LMU Klinikum (DE)
  • National Jewish Medical and Research Center, Denver, Colorado
  • National Heart and Lung Institute, London, United Kingdom
  • Vanderbilt University Medical Center (US)
  • University of Alabama at Birmingham, Birmingham, Alabama
  • Löwenstein Medical (Germany) (DE)
  • Actelion (Switzerland) (CH)
  • University of Washington (US)
Venue
American Journal of Respiratory and Critical Care Medicine
Published
2008-01-01
Volume
177
Issue
1
Pages
75-81
ISSN
  • 1073-449X (ISSN-L)
  • 1535-4970
OpenAlex
W4252692455
Cited by
500
References
30
Citations by year
2026: 7 · 2025: 14 · 2024: 17 · 2023: 15 · 2022: 14 · 2021: 16 · 2020: 20 · 2019: 13 · 2018: 31 · 2017: 26 · 2016: 21 · 2015: 32 · 2014: 28 · 2013: 39 · 2012: 39
FWCI
32.25
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Respiratory and Critical Care Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
Keywords
idiopathic pulmonary fibrosis, bosentan, endothelin receptor antagonists, exercise capacity, 6-minute walk distance, lung function decline, quality of life, dyspnea, open lung biopsy, acute decompensation
MeSH terms
Bosentan, Administration, Oral, Aged, Antihypertensive Agents, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Exercise Test, Female, Forced Expiratory Volume, Humans, Long-Term Care, Male, Middle Aged, Prospective Studies, Pulmonary Fibrosis, Quality of Life, Sulfonamides, Vital Capacity, Survival Rate, Treatment Outcome, Disease Progression, Tomography, Spiral Computed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: BUILD-1: A Randomized Placebo-controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis. https://app.cochat.ai/papers/10.1164/rccm.200705-732oc
The paper
King, T. E., Behr, J., Brown, K. K., du Bois, R. M., Lancaster, L., de Andrade, J. A., Stähler, G., Leconte, I., Roux, S., & Raghu, G. (2008). BUILD-1: A Randomized Placebo-controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.200705-732oc

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.